EA201690383A1 - НОВЫЕ АНТИТЕЛА К FC-γ-РЕЦЕПТОРУ IIB И ИХ ПРИМЕНЕНИЯ - Google Patents

НОВЫЕ АНТИТЕЛА К FC-γ-РЕЦЕПТОРУ IIB И ИХ ПРИМЕНЕНИЯ

Info

Publication number
EA201690383A1
EA201690383A1 EA201690383A EA201690383A EA201690383A1 EA 201690383 A1 EA201690383 A1 EA 201690383A1 EA 201690383 A EA201690383 A EA 201690383A EA 201690383 A EA201690383 A EA 201690383A EA 201690383 A1 EA201690383 A1 EA 201690383A1
Authority
EA
Eurasian Patent Office
Prior art keywords
applications
new antibodies
receptor iib
antibodies
fcγriib
Prior art date
Application number
EA201690383A
Other languages
English (en)
Other versions
EA035855B1 (ru
Inventor
Петер Сондерман
Томас Поль
Доминик Тер Мер
Анна Карле
Даниэла Ээхальт
Николе Рит
Original Assignee
Зуппремоль Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зуппремоль Гмбх filed Critical Зуппремоль Гмбх
Publication of EA201690383A1 publication Critical patent/EA201690383A1/ru
Publication of EA035855B1 publication Critical patent/EA035855B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Microbiology (AREA)

Abstract

Настоящим изобретением предусматриваются антитела к FcγRIIB, которые по сравнению с антителами из уровня техники значительно повышают фосфорилирование ITIM FcγRIIB, и, следовательно, их можно применять для лечения или профилактики аутоиммунных заболеваний.
EA201690383A 2013-08-16 2014-08-13 Новые антитела к fc-гамма-рецептору iib и их применения EA035855B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13004094.2A EP2837637A1 (en) 2013-08-16 2013-08-16 Novel anti-FcyRIIB IgG-type antibody
PCT/EP2014/002234 WO2015022077A1 (en) 2013-08-16 2014-08-13 Novel anti-fc-gamma receptor iib antibodies and uses thereof

Publications (2)

Publication Number Publication Date
EA201690383A1 true EA201690383A1 (ru) 2016-06-30
EA035855B1 EA035855B1 (ru) 2020-08-20

Family

ID=49000296

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690383A EA035855B1 (ru) 2013-08-16 2014-08-13 Новые антитела к fc-гамма-рецептору iib и их применения

Country Status (24)

Country Link
US (1) US10407499B2 (ru)
EP (2) EP2837637A1 (ru)
JP (2) JP6775420B2 (ru)
KR (1) KR102385790B1 (ru)
CN (1) CN105636987B (ru)
AU (1) AU2014308143B2 (ru)
BR (1) BR112016003030A2 (ru)
CA (1) CA2921251C (ru)
CL (1) CL2016000349A1 (ru)
DK (1) DK3033357T3 (ru)
EA (1) EA035855B1 (ru)
ES (1) ES2668482T3 (ru)
HK (1) HK1224302A1 (ru)
HR (1) HRP20180664T1 (ru)
HU (1) HUE038977T2 (ru)
IL (1) IL244135B (ru)
MX (1) MX2016002027A (ru)
MY (1) MY174711A (ru)
NO (1) NO3033357T3 (ru)
PL (1) PL3033357T3 (ru)
PT (1) PT3033357T (ru)
SG (1) SG11201600930RA (ru)
SI (1) SI3033357T1 (ru)
WO (2) WO2015022077A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
KR102424169B1 (ko) * 2014-08-13 2022-07-25 수프레몰 게엠베하 Fc 감마 수용체 iib 및 fc 입실론 수용체에 대한 신규 항체
MA52177A (fr) * 2018-03-26 2021-02-17 Regeneron Pharma Rongeurs humanisés pour tester des agents thérapeutiques

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
DE10157290A1 (de) 2001-11-22 2003-06-05 Max Planck Gesellschaft Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III
CA2495251C (en) * 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
AU2003265522A1 (en) * 2003-08-18 2005-03-10 Macrogenics, Inc. FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
ES2371468T3 (es) * 2003-11-26 2012-01-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. SUSTANCIA QUE SE UNE AL RECEPTOR HUMANO llb MEDIANTE Fc DE IgG (Fc? Rllb).
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB－特异性抗体及其使用方法
KR20070038453A (ko) * 2004-04-16 2007-04-10 마크로제닉스, 인크. ＦｃγＲＩＩＢ-특이적 항체 및 그의 사용 방법
CN1997667A (zh) * 2004-05-10 2007-07-11 宏观基因有限公司 人源化FcγRⅡB特异性抗体及其使用方法
DE602006020333D1 (de) 2005-12-13 2011-04-07 Suppremol Gmbh Multimere fc-rezeptor-polypeptide
EP1870422A1 (en) 2006-06-20 2007-12-26 SuppreMol GmbH Means for the treatment of diseases characterized by an excessive immune reaction
EP2918605A1 (en) 2007-11-12 2015-09-16 U3 Pharma GmbH Axl antibodies
US8802089B2 (en) * 2008-01-03 2014-08-12 Genmab A/S Monoclonal antibodies against CD32B
JP2011526154A (ja) 2008-06-27 2011-10-06 ザイモジェネティクス， インコーポレイテッド 可溶性ハイブリッドＦｃγレセプターおよび関連する方法
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
KR102424169B1 (ko) 2014-08-13 2022-07-25 수프레몰 게엠베하 Fc 감마 수용체 iib 및 fc 입실론 수용체에 대한 신규 항체

Also Published As

Publication number Publication date
EP3033357B1 (en) 2018-02-14
EP2837637A1 (en) 2015-02-18
AU2014308143A1 (en) 2016-03-03
IL244135A0 (en) 2016-04-21
HRP20180664T1 (hr) 2018-07-13
JP2020048562A (ja) 2020-04-02
JP6775420B2 (ja) 2020-10-28
CA2921251A1 (en) 2015-02-19
CA2921251C (en) 2023-01-24
SI3033357T1 (en) 2018-07-31
HUE038977T2 (hu) 2018-12-28
NO3033357T3 (ru) 2018-07-14
BR112016003030A2 (pt) 2017-09-12
EA035855B1 (ru) 2020-08-20
JP2016530256A (ja) 2016-09-29
MY174711A (en) 2020-05-10
WO2015022077A1 (en) 2015-02-19
SG11201600930RA (en) 2016-03-30
KR102385790B1 (ko) 2022-04-12
AU2014308143B2 (en) 2019-10-31
MX2016002027A (es) 2016-05-16
PL3033357T3 (pl) 2018-08-31
WO2015022077A8 (en) 2015-12-03
CN105636987A (zh) 2016-06-01
PT3033357T (pt) 2018-05-18
IL244135B (en) 2020-02-27
DK3033357T3 (en) 2018-05-22
WO2015022076A1 (en) 2015-02-19
US10407499B2 (en) 2019-09-10
CL2016000349A1 (es) 2016-11-04
HK1224302A1 (zh) 2017-08-18
CN105636987B (zh) 2020-07-31
US20160185857A1 (en) 2016-06-30
ES2668482T3 (es) 2018-05-18
KR20160036631A (ko) 2016-04-04
EP3033357A1 (en) 2016-06-22

Similar Documents

Publication Publication Date Title
AU2020264349B2 (en) Anti-PVRIG antibodies and methods of use
CY1122398T1 (el) Συνδυαστικες θεραπειες με αντισωματα anti-cd38
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
EA201890712A1 (ru) Антитела к про-/латентному миостатину и их применения
EA202092435A2 (ru) Моноклональные антитела против bcma
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
MD3370770T2 (ro) Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
NI201700019A (es) Anticuerpos anti tigit
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
EA201892386A1 (ru) Химерные нейротоксины
PH12017500982A1 (en) Heterodimeric antibodies that bind cd3 and cd38
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
MX2020010141A (es) Anticuerpos anti-factor del complemento c1q y uso de los mismos.
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
EA201691974A1 (ru) Антитела против ox40 и способы их применения
EA201691214A1 (ru) Антитела к cd33 и иммуноконъюгаты
EA201691488A1 (ru) Молекулы антител против pd-1 и их применения
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM